Navigation Links
DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium
Date:3/25/2009

Thirteen Abstracts Will Be Featured at Annual Kidney Care Meeting

EL SEGUNDO, Calif., March 25 /PRNewswire/ -- DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney failure and disease (CKD), in conjunction with DaVita Clinical Research(R), today announced that company representatives will present thirteen abstracts at the National Kidney Foundation's 2009 Spring Clinical Meetings scheduled for March 25-29, 2009 in Nashville, TN. The meeting is a platform for the nation's leading renal health care providers to learn about new developments in the field of nephrology and CKD care.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

Allen R. Nissenson MD, Chief Medical Officer at DaVita says, "DaVita is continuing to lead the renal community in generating important new knowledge to improve the outcomes for patients with kidney disease. This commitment to high quality clinical research is clearly evident in the thirteen abstracts being presented at the National Kidney Foundation meeting this year."

DaVita's top ten clinical initiatives for 2009 include: striving for reduction of first-year mortality rates and reducing catheter use. At this year's National Kidney Foundation Clinical Meeting, DaVita will focus on several key research initiatives in the areas of CKD, new incident dialysis patients, and integrated pharmacy management. Highlights from these scheduled presentations will include:

  • Improved Results in CKD Management: Recent data reveals superior outcomes in the areas of CKD and mortality, anemia, incident patient management and phosphorus and coronary artery calcification. DaVita researchers note a nearly 50 percent drop in one-year mortality in Detroit area, DaVita-managed CKD clinics compared to Renal Netwo
    '/>"/>

SOURCE DaVita Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DaVita Clinical Research Completes Record Number of Renal Trials in 2007
2. DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education
3. DaVita Abstracts Highlight Latest Research Developments at Annual Dialysis Conference
4. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
5. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
6. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
7. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
8. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
9. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Company expands reach of ... big data, aerospace and defense, medical, and industrial, ... engineering R&D services company, today announced professional services ... for aerospace and defense , medical ... industrial , and visual computing applications. ...
(Date:7/29/2014)... Israel , July 30, 2014  Immune ... Stockholm : "IMNP."; "Immune" or "the ... of patients for a Phase II proof of concept ... in the treatment of moderate to severe bullous pemphigoid. ... receive two bertilimumab infusions, at a dose of 10 ...
(Date:7/29/2014)... -- Amgen (NASDAQ: AMGN ) today announced ... results include: , Total revenues increased 11 percent ... driven by strong performance across the portfolio, particularly Enbrel ... (denosumab) and XGEVA ® (denosumab). , ... higher revenues and a significant increase in the profitability ...
Breaking Medicine Technology:eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
(Date:7/30/2014)... 2014 Good Neighbor Community Services ... upcoming episode of Innovations with Ed Begley Jr, ... and show times TBA. , In this segment, ... Services’ vision to redefine the traditional approach to ... services. Through passion, innovation, determination, excellence, and collaboration, ...
(Date:7/30/2014)... By Alan Mozes ... -- Parents who want to help their preschooler shed excess ... research suggests. Youngsters whose parents joined them in a ... who were enrolled in a traditional child-only program (an average ... partners also benefited, losing almost 15 pounds over two years, ...
(Date:7/30/2014)... 30, 2014 Volunteers from the Church ... drug abuse this summer with massive distribution of ... can find these volunteers on Strøget, the famous Copenhagen ... for its shopping and its ambiance, some quarter of ... typical summer day. , These activities are part ...
(Date:7/30/2014)... well as evolutionary changes in a living organismhad been ... the genome. , However, recent studies have shown that ... that arise simultaneously and in close proximity to each ... in regions where chromosomal rearrangements take place. , The ... may one day lead to new cancer therapies, according ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 ... authentication, access management and secure communications solutions for ... OneSign ® is the most widely selected single ... Paragon or Horizon electronic medical records (EMR) systems ... of about 11 percent in the last 12 ...
Breaking Medicine News(10 mins):Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2
... Researchers at the University of Texas, have shown that use ... cancer.Up to 70 per cent of US women born since ... suggested that use of the hormones in the Pill could ... have failed to reveal a connection. The early Pill users ...
... to day problem among the adolescents. Every day, more than ... young smokers will eventually die from tobacco-related causes.// A new ... are among the driving forces causing young girls to become ... Institute, followed more than 1,500 young girls, beginning at ages ...
... of taking care your medication. Sometimes half a pill does the ... a medication, or be given a double dose of a medicine ... into two or more doses. ,Doctors at the Mayo ... splitting. First, you need to check if your pill is amenable ...
... darkness might prevent retinal damage in diabetes. One of the ... diabetic retinopathy. This results from damage to the retina //- ... which responds to light.In diabetes, the blood supply to the ... rods (the cells responsible for night vision) which have a ...
... a type of ultrasound test may be able to identify ... most common causes of sudden death in young people.The condition, ... different mutations in as many as 10 genes. In HCM, ... pump blood and putting patients at risk of heart failure ...
... at home reduces hospitalisation in those with lung disease. Researchers ... of oxygen on 200 patients with smoker's lungs - where ... in an outpatient clinic, then continued at home. ... proved to be beneficial. The patients had a 40 per ...
Cached Medicine News:Health News:What makes young girls smoke 2Health News:Ultrasound test may detect heart condition early 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: